A Phase 3 Double-blind, Placebo-controlled Study (Part A) With an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder

Description

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage

Conditions

Generalized Anxiety Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage

A Phase 3 Double-blind, Placebo-controlled Study (Part A) With an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder

Condition
Generalized Anxiety Disorder
Intervention / Treatment

-

Contacts and Locations

Denver

Mountain View, Denver, Colorado, United States, 80209

Lauderhill

Segal Trials, Lauderhill, Florida, United States, 33319

Decatur

iResearch Atlanta, Decatur, Georgia, United States, 30030

Chicago

Uptown Research Institute, Chicago, Illinois, United States, 60640

Watertown

Adams Clinical, Watertown, Massachusetts, United States, 02472

Austin

BioBehavioral Research of Austin, Austin, Texas, United States, 78759

Draper

Cedar Clinical Research, Draper, Utah, United States, 84020

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male or female: must be between 18 (or the legal age of consent in the jurisdiction in which the study is taking place) and 74 years of age inclusive, at the time of signing the informed consent.
  • 2. Diagnosis of GAD per DSM-5.
  • 3. HAM-A Total Score ≥20.
  • 1. Any psychiatric disorder (other than generalized anxiety disorder).
  • 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder.
  • 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine).
  • 4. Any clinically significant unstable illness.

Ages Eligible for Study

18 Years to 74 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mind Medicine, Inc.,

Study Record Dates

2027-06-03